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External quality assessment of tumour marker analysis:
state of the art and consequences for estimating
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Ringversuche für Tumormarker: eine Istanalyse mit Folgerung für die
Berechnung der diagnostischen Sensitivität und Spezifität
Abstract
Thisreviewshowsthecurrentanalyticalqualityforthefollowinganalytes
used as tumour markers in the external quality assessment (EQA)-pro-
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gonadotropin (CG, hCG), calcitonin (CT, hCT), thyroglobulin (Tg), car- 1 Instand Reference
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cinoembryonic antigen (CEA), CA-Antigens 125, 72-4, 15-3 and 19-9,
alpha foetoprotein (AFP) and prostate-specific antigen (PSA).
The results from the participants show a large variation in the precision
of the methods used as well as in the comparability of results between
methodsforthesameanalyte.Ingeneral,thehormonesusedastumour
markers show better performance than the "CA-markers", which are
often inadequately standardised and defined. In the case of one CA-
marker (CA 72-4/TAG 72-4), the differences between the lowest kit
median concentration and highest kit median concentration for one
sample pair were 440% and 580%. The corresponding figures for ACTH
were 123% and 156% and for CEA 180% and 184%.
The classical tumour markers such as carcinoembryonic antigen (CEA)
and alpha foetoprotein (AFP) performed markedly better than the CA-
markers and PSA with regards to both inter- and intra-method compar-
ability.
Theinter-laboratoryprecisionforagivenkitandmarkerwasacceptable
in many cases.
The results show that only results from the same kit/method for each
tumour marker can be used for cumulative or time-dependent compar-
ison of results - for example pre-operative and post-operative follow up.
In the case of prostate specific antigen (PSA), the kits used for free and
total PSA must come from the same producer, if the generally accepted
ratios are to have any diagnostic value.
The need for kit- and laboratory-specific reference ranges and cut-off
values for setting diagnostic specificity and sensitivity is highlighted
from the EQA-results. The situation for inter-method comparability for
the CA-Markers has not improved over the past decade.
With the exception of calcitonin for detecting medullary thyroid car-
cinoma, chorionic gonadotropin in germ-cell tumours in men and
thyroglobulin after total thyroidectomy, none of the remaining analytes
appear to be suitable for screening purposes.
Keywords:externalqualityassessment(EQA),tumourmarkers,precision,
accuracy, standardisation, method comparison, diagnostic specificity,
diagnostic sensitivity, immunoassay
Zusammenfassung
DieseÜbersichtstelltdieanalytischeQualitätvoneinigenTumormarkern
indenRingversuchendar.EshandeltsichumdieAnalyte:Corticotropin
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Review Article OPEN ACCESS(ACTH),Wachstumshormon(GH,hGH),Prolaktin(PRL),Choriongonado-
tropin(hCGundCG),Calcitonin(CT),Thyreoglobulin(Tg),Carcinoembryo-
nales Antigen (CEA), CA-Antigene 125, 72-4, 15-3 und 19-9, Alpha-Fe-
toprotein (AFP) und Prostata-spezifisches Antigen (PSA). Die Analysen-
ergebnisse der Ringversuchsteilnehmer weisen eine relativ große Un-
präzision und mangelhafte Vergleichbarkeit bei demselben Analyten
auf.LediglichbeidenHormonen,soweitsiealsTumormarkerverwendet
werden,sinddieAnalysenergebnissebesservergleichbaralsdiejenigen
der anderen Protein-Tumormarker, bei denen offenbar eine durchgrei-
fende Standardisierung noch aussteht. Als Beispiel sei genannt der
Analyt CA 72-4 (TAG 72-4), bei dem die Unterschiede der Medianwerte
der verschiedenen Analyseverfahren zum Teil 440% - 580% betragen.
Für ACTH waren die vergleichbaren Zahlen 123% und 156%, für CEA
180% - 184%. Die klassischen Tumormarker wie AFP und CEA erzielten
bessere Ergebnisse als die CA-Marker und PSA.
Die Ergebnisse der Studie zeigen, dass für die Langzeitüberwachung
von Patienten nur das gleiche Analysesystem bzw. der gleiche Testkit
eingesetzt werden darf. Für Prostata-spezifisches Antigen sollten die
Reagenzien zur Bestimmung von gesamt- und freiem PSA vom selben
Hersteller bezogen werden und auf äquimolarer Basis funktionieren.
Jedes Labor sollte seine eigenen Referenzbereiche und cut-off Werte
für jeden Tumormarker selbst erstellen oder vom Hersteller angeben
lassen. Die Übernahme von cut-off Werten aus Lehrbüchern für alle
Analysensysteme ist nicht angezeigt. Bedauerlicherweise hat sich die
Vergleichbarkeit zwischen den Reagenziensystemen für die CA-Marker
von verschiedenen Herstellern über die letzten Jahre nicht wesentlich
verbessert.
Mit Ausnahme von Calcitonin zur Diagnose von medullären Schilddrü-
senkarzinomen,ChoriongonadotropinfürKeimzelltumorenbeiMännern
und Thyreoglobulin nach totaler Thyreoidektomie ist keiner der aufge-
führten Marker für das Tumor-Screening geeignet.
Introduction
Theconceptofusingmarkersforthemonitoringoftumour
growth and efficiency of therapeutic intervention is not
new. The first attempts at monitoring tumour growth
and/or activity were with monoclonal immunoglobulino-
pathies using electrophoretic techniques and endocrine
tumours using hormones as markers. The chemical ana-
lysis of hapten hormones such as adrenaline, noradren-
aline, serotonin in urine or plasma and their metabolites,
homovanillic acid, vanillylmandelic acid and 5-hydroxyin-
doleaceticacidinurinewereusedasdifferentialmarkers
forsuprarenalneoplasia(neuroblastoma,phaeochromo-
cytoma, carcinoid) [1], [2], [3], [4]. Tartrate-inhibited acid
phosphatase (ti-AcP) was used as an indicator of benign
or malignant prostatic disorders [5].
The introduction of immunoassays allowed the measure-
ment of peptide hormones, at first mainly for pituitary
disorders (corticotropin (ACTH), growth hormone (GH,
hGH), chorionic gonadotropin (CG, hCG), prolactin (PRL),
thyrotropin (TSH)), steroid hormones (cortisol, aldoster-
one) and thyroid hormones (thyroxine (T4) and triiodo-
thyronine (T3)) [6], [7], [8], [9], [10], [11], [12].
The search for more specific markers for non-endocrine
tumours led to the development of carcinoembryonic
antigen (CEA), alpha foetoprotein (AFP) and the "CA-im-
munoassays",originallyfromCentocor.Thelatterinclude
CA 19-9 (gastrointestinal tumours), CA 125 (ovarian
cancer), CA 15-3 (breast cancer) and CA 72-4 (TAG 72-4,
gastric tumours) [13], [14], [15], [16], [17], [18].
The use of prostate-specific antigen (PSA) as a more
specific tumour marker became interesting after the
discovery that PSA was present in at least three forms in
serum(freeandcomplexedwitheitherα1-antichymotryp-
sin (α1-ACT) and α2-macroglobulin (α2-MG), the latter of
which is not detectable by immunoassay, as the PSA is
surrounded by the α2-MG and is therefore "invisible" to
antibodies). Assays were developed for total, free and
complexed PSA [19], [20], [21]. The ratio of "free" PSA to
complexed PSA (= PSA-α1-ACT) has been propagated as
being able to differentiate between benign (hyperplasia)
and malignant (neoplastic) prostatic disease [22], [23].
With the advent of the polymerase chain reaction (PCR)
- methods, the accent of diagnosis is shifting toward the
use of genetic markers. Examples here are the BRCA-1
and BRCA-2 genes which are associated with breast and
ovarial cancer [24], [25], [26].
This publication deals with the review of tumour-marker
external quality assessment (EQA) - schemes offered by
Instand e.V. with a critical appraisal of performance and
method comparability and their influence on the estima-
tion of the diagnostic sensitivity and specificity.
Thelargevariationinkit-performance,asfarasnumerical
values are concerned, raises the question as to whether
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Reinauer et al.: External quality assessment of tumour marker analysis...Table 1: 1-39 ACTH - EQAS results - arranged according to methods
ACTH concentrations in ng/l
the "cut-off" values generally accepted but not validated
for each method/kit, are of any use in terms of setting
limits for diagnostic sensitivity and specificity.
Materials and methods
The data used in this publication was obtained from the
EQAschemesrunbyInstande.V.during2003and2004.
Two samples - lyophilised processed serum for the pro-
teohormones, thyroglobulin and α-foetoprotein; liquid
processed serum for the CA-markers, carcinoembryonic
antigenandprostate-specificantigen-containigdifferent
analyte concentrations were sent for analysis with each
survey.
Participants were requested to return the analysis data
together with details concerning the measuring device
and method/kit used.
Data was used from EQA-schemes for the following ana-
lytes: calcitonin (CT, hCT), thyroglobulin, α-foetoprotein
(AFP), chorionic gonadotropin, prolactin, corticotropin,
prostate-specific antigen (free, total and complexed: f-
PSA; t-PSA; c-PSA), carcinoembryonic antigen (CEA), CA-
125, CA 19-9, CA 72-4 and CA 15-3.
Statistics
Any statistical comparisons used were based on the cal-
culation of the measure of central tendency (mean, me-
dian) and dispersion (standard deviation and coefficient
of variation (normally distributed data)) defined confid-
enceintervalsascentiles(non-Gaussiandatadistribution)
and mainly included box and whisker plots and data dis-
tribution curves for graphic illustration of group-results.
Statistical comparisons between methods for a given
analyte were not made because the study was designed
to present data in a visual way, rather than to compare
the inter-method performance.
Results
Theresultsaregivenseparatelyforeachanalyte.Samples
1 and 2 were the same pair in Tables 1-3. Sample 1 was
pooled adult male serum, Sample 2 pooled adult female
serum. Both samples were spiked and filtered (0.2 µm
pore size).
Generally accepted cut-off levels for the "CA-Markers",
CEA and total PSA have been given in the text [27], (see
also[28]).These"decision-limits"haveusuallybeenmade
many years ago for assay-designs (e.g. competitive ra-
dioimmunoassay) no longer existing. They have not been
validatedforimmunometricmethodsandshouldbeinter-
preted with care.
Therearenosuch"dogmatic-limits"fortheotheranalytes
used as tumour markers.
a. Corticotropin (1-39 ACTH)
The problems with 1-39 ACTH are due more to stability
oftheanalytethantoanalyticalproblems,althoughsome
kits react more "allergically" than others.
Table 1 shows the results from three samples sent in
different EQA-surveys in 2004.
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Growth hormone concentrations in µg/l
Table 3: Prolactin - EQAS results - arranged according to methods
Prolactin concentrations in µg/l
b. Growth Hormone (GH, hGH)
At present, kits are using both the 1
st IS, which is an ex-
tractfromhumanpitutitaries,aswellastherecombinant
22kD2
ndIS.Thecomparisonbetweenkitsissogoodthat
allkitsusingthesamereferencestandardcanbegrouped
together. The values obtained using the recombinant
material are substantially lower than those from the ex-
tracted human pituitaries.
Table 2 shows the results for growth hormone assays
from three samples sent in different EQA-surveys (EQAS)
in 2004.
c. Prolactin (PRL)
Prolactinkitswerecalibratedexclusivelywiththe3
rdinter-
nationalstandard.Table3showstheresultsforprolactin
results from three samples distributed in 2004.
d. Chorionic Gonadotropin (CG, hCG)
Thekitsweredividedintothosemeasuringonlyholo-hCG,
holo-hCG + free β-chain and only free β-chain. Results
were given as method specific in the first two cases and
as a single group in the latter case.
The calibration of methods for holo-hCG was with the 3
rd
IS (NIBSC 75/537), for free β-chain with the 1
st IRP for
immunoassay (NIBSC 75/551). Accurate calibration of
kits which determine both holo-hCG and free β-chain is
impossible, as there are two unknown variables. Both
reference preparations are given in IU/ampoule, but 1 IU
holo-hCG is not equal to 1 IU free β-chain. The specificity
oftheantibodiesforholo-hCGiswelldocumentedinTable
4. The cross-reactivity of the free β-chain in the "mixed"
assays can be seen by comparing the values for samples
1 and 2 in Tables 4 and 5 . The results from three EQA
samples sent in 2004 are shown in Tables 4-6 .
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hCG concentrations in IU/l (NIBSC 75/537)
Table 5: Holo-hCG + free β-chain - EQAS results - arranged according to methods
Table 6: Free β-chain - EQAS results - arranged according to methods
β-hCG concentration in IU/l (NIBSC 75/551)
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Calcitonin concentration - ng/l
Table 8: Thyroglobulin - EQAS results - arranged according to methods
Thyroglobulin concentration - µg/l
e. Calcitonin (CT, hCT)
The assays for calcitonin must be able to recognise very
highvaluesassuch,sothatahigh-dosehookeffectmust
be eliminated from hCT-assays. The concentrations of
calcitonin seen in the serum of unoperated medullary
thyroid caricinoma (MCT) patients is in the ng/l to mg/l
range. The physician requires accurate pre- and post-op-
erative values in order to assess the success of the oper-
ation. Values "greater than" are of little or no use here.
The results from three EQA-samples distributed in 2004
are shown in Table 7.
f. Thyroglobulin (Tg)
Thekitsmustmeasurepreciselyatthelowestconcentra-
tion possible (≤2 µg/l) if they are to be used as tumour
markers after total thyroidectomy, where recurrence of
thyroglobulin in serum or plasma indicates metastatic
growth. The precision of the kits shown in Table 8 is ac-
ceptable at all three levels controlled. Kit 5b measures
precisely,butconsistentlyhigherthantheothermethods.
This could prove a problem for the physician responsible
for monitoring thyroid cancer if the laboratory changed
methods - for example from manufacturer 3 to manufac-
turer5-andthisinformationfailedtoreachthephysician.
g. Carcinoembryonic Antigen (CEA)
CEAisgenerallyusedinassessingcolorectalcancersand
liver metastases. The generally accepted cut-off values
for CEA are between 1.5 and 5 µg/l, depending upon the
kit used.
Table 9 shows the results from different manufacturers
for CEA Kits in 2 samples dispatched in 2002. Samples
wereliquidandwerecommerciallypreparedfrompooled
patient sera specially for Instand e.V.
Themedianvaluesforeachmethod/method-groupvaried
by up to 85%.
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Reinauer et al.: External quality assessment of tumour marker analysis...Table 9: Carcinoembryonic antigen - EQAS results - arranged according to methods
CEA concentration - µg/l
Table 10: CA 15-3 - EQAS results - arranged according to methods
CA 15-3 concentration - kU/l
h. CA 15-3
CA15-3isusedinthein-vitromonitoringofbreastcancer.
The generally accepted cut-off value for CA 15-3 is 25
kU/l, independent of the kit used.
Table 10 shows the results for CA 15-3 for the same
samples as in Table 9.
Theinter-kitcomparisonofthedistributionofresultswas
comparable for both samples (variation of the method-
median: Sample 1 - 44%; Sample 2 - 42%).
i. CA 19-9
CA 19-9 is often used in conjunction with CEA in monitor-
ingintestinalcancer.Thegenerallyacceptedcut-offvalue
for CA 19-9 is 37 kU/l.
Table 11 shows the results for CA 19-9 for the same
samples as in Table 9. Figure 1 shows a box and whisker
plot for Sample 2 in Table 11.
The inter-kit comparison was not comparable for both
samples (variation of the method-median: Sample 1 -
116%;Sample2-140%).Themethodcomparisonresults
for CA 19-9 was worse than for CA 15-3.
j. CA 125
CA 125 was found to be useful in monitoring ovarian
cancer. The generally accepted cut-off level for CA 125
is 35 kU/l.
Table 12 shows the results for CA 125 for the same
samples as in Table 9.
The inter-kit comparison was again not comparable for
both samples (variation of the method-median: Sample
1 - 162%; Sample 2 - 108%). The inter-kit variation was
similar to that for CA 19-9.
k. CA 72-4
CA 72-4 (formerly known as Tennessee Antigen (TAG)) is
used in the follow-up of gastric cancer. The generally ac-
cepted cut-off level for CA 72-4 (TAG 72-4) is 4 kU/l.
Table 13 shows the results for CA 72-4 (TAG 72-4) for
the same samples as in Table 9.
The inter-kit comparison was comparable for both
samples (variation of the method-median: Sample 1 -
445%; Sample 2 - 576%). The variation of results from
differentkitswasthegreatesthere,althoughonekit(5b)
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CA 19-9 concentration - kU/l
Figure 1: Spread of results for Sample 2 in Tab. 11 listed according to kit/method
The kit/method is shown on the abscissa and in the legend, the CA 19-9 concentrations on the ordinate.
The values between the lower and upper quartiles (25
th-75
th centiles) are within the box. The whiskers represent the limits ±1.5
x (75
th -25
th centile values). Outliers are shown as filled circles. The median is shown by the horizontal line within the box.
The number of participants for each kit/method is given in Tab. 11.
gavemuchlowerresultsthattheotherkits.Evenanother
kit offered by the same manufacturer (5a) gave results
between 6 and 7 times higher than kit 5b. This reflects
the absence of standardisation in the determination of
the "CA"- tumour markers as a whole, with perhaps the
exception of CA 15-3.
l. Alpha-Foetoprotein (AFP)
Alpha foetoprotein has mainly been used for monitoring
primary hepatic cancer. The accepted range for healthy
non-pregnantindividualsis≤7kIU/l(≈10µg/l)(calibrated
with NIBSC 72/225).
Table 14 shows the results for AFP for the same samples
as in Table 9.
The inter-kit comparison of results is much better than
for the "CA"-markers, the variation of the kit-medians for
Sample 1 being 25% and for Sample 2, 22%. This may
be due to the fact that all AFP kits have been calibrated
against the WHO Standard (NIBSC 72/225), which is no
longer available.
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Reinauer et al.: External quality assessment of tumour marker analysis...Table 12: CA 125 - EQAS results - arranged according to methods
CA 125 concentration - kU/l
Table 13: CA 72-4 - EQAS results - arranged according to methods
CA 72-4 concentration - kU/l
Table 14: Alpha-foetoprotein - EQAS results - arranged according to methods
AFP concentration - µg/l
m. Total Prostate-Specific Antigen (t-
PSA); Free PSA (f-PSA); Complexed PSA
(c-PSA)
The various forms of circulating prostate-specific antigen
(PSA) have been widely used - both singly and in combin-
ation - to monitor and differentiate between benign and
malignantdisordersoftheprostate.Thegenerallyaccept-
ed cut-off for t-PSA is 4 µg/l. The ratios between t-PSA
andf-PSAorc-PSAandf-PSAarestrictlymethod-depend-
ent. t-PSA assays may be calibrated with the first interna-
tionalstandard(NIBSC96/670),amixtureofc-PSA(90%)
and f-PSA (10%).
Table 15 shows the results for t-PSA, Table 16 for f-PSA
and Table 17 for c-PSA in the same samples as for Table
9.
The difference in specificity of the antibody-pairs for PSA
determination can be seen in Tables 15 and 16 . The
material used for spiking was from seminal fluid, known
tobemainlycomposedoffreePSA.Whereaskit5bdiffer-
entiated well between "total" and "free" PSA, kit 6a
measured more free PSA than total PSA! The results in
Table 17 shows the amount of PSA-α1-antichymotrypsin
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PSA concentration - µg/l
Table 16: Free PSA - EQAS results - arranged according to methods
Free PSA concentration - µg/l
Table 17: Complexed PSA - EQAS results - arranged according to methods
Complexed PSA concentration as µg/l PSA (not µg/l PSA-ACT complex)
(PSA-ACT) in each sample, which is usually much more
abundantthanfreePSAandreflectsthenon-physiological
nature of both samples, due to the reason stated above.
Figures 2 and 3 show the results from Tables 15-17 in
the form of a box-and whisker plot.
There were large variations in the median values from
both total and free PSA kits as can easily be seen in Fig-
ures 2 and 3 .
Discussion
TheresultsfromtheEQA-surveysshowthatthestandard-
isation of assays used as tumour markers is in many
casesfarfrombeingoptimised.Thedatapresentedshow
that at the present time the hormone assays used for
tumour monitoring are on the whole more precise and
giverisetomorecomparableresultsthantheless-specific
mucin-carbohydrate "CA-markers" and the various circu-
lating forms of PSA.
Theproblemsoftumourmarkermeasurementhaveboth
a physiological and methodological component. For ex-
ample the determination of CA 19-9, a marker related to
the Lewis-antigens [29], [30], [31] is not produced in
patients who are both Lewis a and Lewis b negative [31].
This means, that such patients can have large intestinal
tumours,whichare"negative"forCA19-9inserum.Many
tumour markers are influenced by renal function, so that
dialysis patients and those with impaired renal function
mayhavedifferent(mostlyelevated)concentrationswhen
compared with patients with normal renal function [32],
[33]. Others, such as AFP, are increased in pregnancy.
There are very few "specific" tumour markers. Examples
are calcitonin (CT) in medullary thyroid cancer (MTC) and
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The layout for Fig. 2 is identical to that in Fig. 1.
Figure 3: Spread of results for free (10 kits/methods) and complexed PSA (1 kit)
The layout for Fig. 3 is identical to that in Fig. 1.
thyroglobulin (Tg) in thyroidectomised patients, although
the latter may be masked by the presence of circulating
antibodiestoTg.Elevatedlevelsofchorionicgonadotropin
(CG)isrelativelyspecificinmalesasamarkerofgerminal-
cell cancer.
The commercial interest in tumour-markers cannot be
ignored, both from the side of kit-producers as well as
from kit-users. The clinical use is far more restricted,
many "tumour markers" not being able to fulfil their spe-
cifications with regard to both analytical and diagnostic
sensitivity and specificity. Clinical decisions made purely
on levels of tumour markers - with the exception of per-
haps CT, Tg and CG in males - must be seen as irrespons-
ible, especially in a decentralised health system with the
free choice of analytical laboratory and methods used.
The EQA results clearly show that the comparability of
results and continuity in monitoring patient progress is
onlypossiblewhenusingthesamemethodwiththesame
components over a long period of time. The danger of
"rationalisation"and"cost-saving"(=buyingthecheapest
kit offered) practiced by many administrators, coupled
with the ignorance of the medical staff on the methodo-
logical problems mentioned above, further limits the
qualityofdataobtainedfromanalysing"tumourmarkers".
11/15 GMS German Medical Science 2005, Vol. 3, ISSN 1612-3174
Reinauer et al.: External quality assessment of tumour marker analysis...Figure 4: Data for setting diagnostic sensitivity and specificity
as histograms
Fig. 4 shows the ideal situation where healthy (red) and sick
(blue) patients are clearly separated from each other. The
abscissa shows the analyte concentration, the left ordinate the
frequencyineachcolumn.Therightordinateshowstherelative
frequency distribution (Value: 0=0%; 1=100%).
Figure 5: Smoothed data distribution curves for the data
in Fig. 4
The abscissa and left ordinate are as in Fig. 4.
The effect of numerical values can be visualised in com-
paring the diagnostic sensitivity (the correct prediction
of a positive (=tumour present) result) and diagnostic
specificity (the correct prediction of a negative (=tumour
not present) result). Figures 4 and 5 show the ideal case
for a tumour marker, where healthy (red) and sick (blue)
patientsareclearlyseparatedfromeachother(diagnostic
sensitivity and specificity 100%). Figures 6 and 7 show
the more common situation, i.e. where both groups
overlap. In Figure 7, there are three ways of setting a
decision point. At point A we have the lowest analyte
concentration where all sick patients are correctly allo-
cated (diagnostic sensitivity 100%). A number of healthy
patients have however concentrations higher than this
point (diagnostic specificity <100%) and would be classi-
fied as sick. At point B we have the converse situation -
the highest concentration where all healthy individuals
are correctly classified (diagnostic specificity 100%), but
where some sick individuals (those under the blue curve
to the left of B) are to be found (diagnostic sensitivity
<100%)andareclassifiedwronglyasbeinghealthy.Point
C represents the best compromise where the degree of
false classification is minimised, but where sick and
healthy individuals in the border region may be wrongly
classified (diagnostic sensitivity and specificity in this
case <100%).
Figure 6: Data for setting diagnostic sensitivity and specificity
as histograms
Fig.6showstherealsituationwherethegroupsofhealthy(red)
andsick(blue)patientsoverlap.Theabscissashowstheanalyte
concentration, the left ordinate the frequency in each column.
The right ordinate shows the relative frequency distribution
(Value: 0=0%; 1=100%).
Figure 7: Smoothed data distribution curves for the data
in Fig. 6
Fig. 7 shows the analyte concentration for 100% diagnostic
sensitivity(A)and100%diagnosticspecificity(C).PointBshows
the compromised "real-life" situation, where both diagnostic
sensitivityandspecificityarelessthan100%.Theabscissaand
ordinates are as in Fig. 6.
In the case of t-PSA, if we leave the points A, B and C in
Figure 7 where they are and measure patient sera with
themethodsinTable15,itbecomesobviousthatthered
and blue curves will be moved - either to the right or to
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Reinauer et al.: External quality assessment of tumour marker analysis...Figure 8: Data for Sample 2 in Tab. 15 (total PSA) highlighting the variabilty of measurement, both in absolute concentration
and precision for the different kits on the market
The abscissa and ordinate are as in Fig. 5 and 7.
the left - thus changing the diagnostic sensitivity and
specificity according to the method/kit used. The points
A,B and C must be evaluated for each kit.
Figure 8 shows the distribution of data of the t-PSA
Sample 2 in Table 15. Both the mean values and preci-
sion of measurement (seen by the different degrees of
kurtosis)makeitclearthatthevariabilityinmeasurement
-heretakingt-PSAastheexample-mustleadtodifferent
kit-specific cut-off values, thus nullifying a static point of
decisionat4µg/l.Bothextremesareshownbythepoints
A (Kit 11a) and B (Kits 8a, 10a and 15c).
Standardisation of methods - not with international anti-
gen preparations but with defined antigenic epitopes re-
cognised by defined monoclonal antibodies, as in the
case of the tumour marker Cyfra 21-1 [34], can lead to
more comparability between manufacturers and to an
improvement in the interpretation of results by clinical
staff, thus improving the benefits to patients subjected
to such analyses.
Method-dependent differences in results, especially in
the case of PSA, make it imperative that method-specific
referencerangesand"cut-off"valuesmustbeestablished
foreachanalyte.InthecaseofPSA,whereratiosbetween
free and total PSA or complexed and total PSA are used
indifferentiatingbetweenbenignandmalignantdisease,
kits from the same manufacturer must be used for free
andtotal/complexedPSA,iftheratiosgivenbythemanu-
facturer are to have any clinical use. General reference-
ranges and ratios often given in text books are of no use,
due to the individual nature of results from different
manufacturers,althoughsomeauthors[35]pointoutthe
importance of using kit-specific reference ranges. The
importance of this is shown in Tables 15 and 16 above,
eventhoughthesampleswerenotphysiological(concen-
tration of free PSA much higher than complexed PSA).
Even kits from the same manufacturer, but developed
for different instruments with different measuring tech-
niques may give rise to statistically different results from
the same sample - here seen in kits 41 and 42 for t-PSA.
Theuseofgeneralisedfiguresforthediagnosticsensitiv-
ity and specificity of tumour-marker kits must be discour-
aged, as seen in the results from this study (as an ex-
ample, see Figure 1). Each laboratory must therefore es-
timate its own diagnostic sensitivity and specificity for all
tumour-markers from data obtained from the kit used
and the group(s) of patients studied. The relatively low
diagnostic sensitivity and/or specificity shown by many
tumour-markers reflects their inability to be used for
screening purposes. Despite this, medical staff still use
tumour markers for patient screening - especially PSA -
although no prospective randomised trial has been per-
formed to validate or reject the use of PSA in screening
for prostate cancer [36]. Recently, the value of PSA in
diagnosis and monitoring of prostate cancer has again
been questioned [37]. Even in review articles, the cut-off
fort-PSAdecisiontakingissetat4µg/l,despiteevidence
formethoddependentreferencerangescitedinthesame
article [38]!
Eveninthecaseofpost-operativefollowup,itispossible,
that when metastasis occurs, "tumour-specific-antigens"
may be produced which are structurally different from
those in the primary tumour, thus rendering the further
use of the original marker for follow-up useless.
The future of detection and post-operative follow-up of
tumours may very well lie in the developing field of gene-
expression chips [39]. That synthesis of tumour markers
can change during the development of neoplasms has
been shown in immunohistochemical studies [40].
Even the use of genetical markers can at present only
predict a predisposition for - in this case - the develop-
ment of a certain tumour. The time of appearance of the
lesion cannot be predicted from the presence of or
mutations in certain genes - for example BRCA-1 [24],
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ovarian cancer before the 5th decade of life.
Classicalmethodsofdetectionandcontrol,suchasx-ray,
sonography, PET, MRT and computer tomography, will
remain the "golden" standards of tumour detection and
control of tumour progression/remission for many years
to come, although "gene-chips" will play an increasingly
important role in detection of those at risk, as well as
post-operative follow-up of cancer patients [41], [42],
[43], [44].
To conclude, the majority of analytes used as tumour
markers are unsuitable for screening purposes. Excep-
tions are the measurement of calcitonin, chorionic gon-
adotropin and thyroglobulin when used in the situations
stated above. The use of the other analytes reported in
this article may be of use in longitudinal follow-up pre-
andpost-operatively,withtherestrictionthatthemethod
used for a given analyte must always be the same, at
least until both an acceptable standardisation of meth-
ods/results and comparability of numerical values (con-
centrations)isachieved.Thelatterhasnotbeenrealised
and is not to be expected in the near future, at least for
themajorityofanalytes.Untilthen,definedindividualcut-
off values must be established for each tumour marker
kit on the market.
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